''The Committee recommend that all medical devices critical to...
Category:
Pandemic
Latest
Global Covid caseload tops 472 mn, fatalities surge past 6.09 mn
The US continues to be the worst-hit country with the world's...
Govt considers widening Covid booster shots to all adults in India: Report
The government is debating whether to provide boosters to other...
Centre asks states for data on Covid deaths due to oxygen shortage: Report
The government’s reply comes in the aftermath of the devastating second COVID-19 wave that overwhelmed the country’s healthcare infrastructure and resulted in thousands of deaths daily. COVID-19 cases surged dangerously from April to June and peaked in May with over 4-lakh cases and 4,000 deaths.
Govt panel recommends nod to SII for phase 2/3 trials of Covovax on children aged 2-17
Union Health Minister Mansukh Mandaviya on Tuesday told BJP MPs that Covid vaccination for children is likely to start soon, sources said.
NPPA has fixed ceiling prices of 355 medicines, 882 formulations: Mandaviya
”Most of the drugs that are part of COVID-19 management protocol have ceiling prices, viz., paracetamol, dexamethasone, methylprednisolone, IVIGs, enoxaparin, budesonide, heparin and amphotericin, etc,” Minister of Chemicals and Fertilisers Mansukh Mandaviya said in a written reply to a query in the Lok Sabha.
In the case of few non-scheduled medicines like remdesivir, which are part of COVID-19 protocol and are non-scheduled, on government intervention, MRPs of various brands of remdesivir have been reduced voluntarily by the major manufacturers/marketers of the remdesivir injection (lyophilized), he added.
Inter-brand maximum retail prices (MRPs) that varied up to Rs 5,400 per vial were brought down to less than Rs 3,500, the minister said.
WHO has commenced review process for emergency use listing of Covaxin: Govt
Responding to a question on whether it has come to the notice of the government that COVID-19 vaccine Covaxin used in India is not recognised by many countries, Pawar said the government is aware that Covaxin at present is not part of WHO Emergency Use Listing (EUL).
India records less than 30,000 fresh COVID-19 cases in over three months
Pfizer, Astra vaccine antibody levels may decline after 2-3 months: Lancet
“When we are thinking about who should be prioritised for booster doses our data suggests that those vaccinated earliest, particularly with the AstraZeneca vaccine, are likely to now have the lowest antibody levels,” said Professor Rob Aldridge from UCL Institute of Health Informatics.
22 districts recorded increasing trend in COVID cases, 54 districts report 10 pc positivity: Health Ministry
While addressing a press briefing here, Union Health Ministry Joint Secretary Lav Agarwal said, “There are 22 districts — 7 from Kerala, 5 from Manipur, 3 in Meghalaya among others, where an increasing trend in cases has been reported, in the last 4 weeks. It is a cause of concern.” Agarwal said there are still 62 districts in the country where over 100 cases are reported every day, which are found in a localised and limited set of areas of these districts.
Made in India Sputnik V to be available during September- October- Dr Reddy s
Dr. Reddy, which has tied up with the Russian Direct Investment Fund for Sputnik V in India, soft-launched the vaccine in India in May 2021 after receiving Emergency Use Authorization (EUA) in April 2021.
U.S. will not lift travel restrictions, citing Delta variant -White House
U.S. Centers for Disease Control and Prevention (CDC) director Rochelle Walensky said on Thursday the seven-day average of new cases in the United States was up 53% over the previous week. The Delta variant, which was first found in India, now comprises more than 80% of new cases nationwide and has been detected in more than 90 countries. Psaki also cited the fact that last week, the CDC urged Americans to avoid travel to the United Kingdom, given a jump in cases.
IMF cuts India’s GDP growth forecast to 9.5 pc for FY22
IMF joins a host of global and domestic agencies which have cut India’s growth estimates for the current fiscal. Last month, S&P Global Ratings projected a 9.5 per cent GDP growth in the current fiscal and 7.8 per cent in 2022-23.
IMF’s Chief Economist Gita Gopinath said IMF estimates the pandemic has reduced per capita incomes in advanced economies by 2.8 per cent, relative to pre-pandemic trends over 2020-2022, compared with an annual per capita loss of 6.3 per cent a year for emerging market and developing economies (excluding China).